01.08.2016 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises 2016 earnings guidance


 
Fresenius SE & Co. KGaA / Key word(s): Change in Forecast 01.08.2016 22:49 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fresenius raises 2016 earnings guidance Based on the Group's excellent financial results in the first half of 2016 and strong prospects for the remainder of the year, Fresenius raises its 2016 Group earnings guidance. Net income* is now expected to grow by 11% to 14% in constant currency. Previously, Fresenius expected net income* growth of 8% to 12% in constant currency. The company confirms its Group sales guidance. Sales are expected to increase by 6% to 8% in constant currency. Fresenius Kabi also raises its outlook for 2016 and now expects organic sales growth of 3% to 5% and EBIT** growth in constant currency in the range of 3% to 5%. Previously, Fresenius Kabi projected low single-digit organic sales growth and EBIT** in constant currency to be roughly flat compared with 2015. * Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before special items ** 2015 before special items For additional information on the performance indicators used please refer to pages 25, 40, 56f., 100f. and 194 of the Annual Report 2015 of Fresenius SE & Co. KGaA. Constant currencies for income and expenses are calculated using 2015 average rates (cf. Annual Report 2015, page 111). (https://www.fresenius.com/financial_reporting/ Fresenius_GB_US_GAAP_2015_englisch.pdf). (Financial statements according to U.S. GAAP) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, Board of Management Bad Homburg v.d.H., August 1, 2016 Contact: Markus Georgi Senior Vice President Investor Relations T: +49 (0) 6172 608-2485 [email protected] End of note 01.08.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 29.083,00 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 39.695,00
EBITDA1,2 5.500,00 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 0,00
EBITDA-Marge3 18,91 18,69 17,04 19,01 19,66 18,27 0,00
EBIT1,4 4.327,00 4.589,00 5.251,00 4.631,00 4.385,00 4.252,00 4.990,00
EBIT-Marge5 14,88 13,69 14,83 12,43 12,09 11,33 12,57
Jahresüberschuss1 2.676,00 1.816,00 1.871,00 1.915,00 2.823,00 1.867,00 2.035,00
Netto-Marge6 9,20 5,42 5,28 5,14 7,78 4,98 5,13
Cashflow1,7 3.574,00 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 5,58
Ergebnis je Aktie8 2,83 3,25 3,37 3,44 3,06 3,26 2,45
Dividende8 0,62 0,75 0,80 0,84 0,88 0,92 0,70
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 27,820 Kaufen 15.669,26
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,65 17,06 0,73 9,52
KBV KCV KUV EV/EBITDA
0,85 3,09 0,42 5,84
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
Hauptversammlung
0,70 0,70 2,52 17.05.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
09.05.2023 02.08.2023 01.11.2022 24.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,31% 5,03% 5,98% -25,48%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE